Johnson & Johnson (NYSE:JNJ) Releases Quarterly Earnings Results

Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings results on Wednesday. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09, Zacks reports. The company had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.82 earnings per share. Johnson & Johnson updated its FY 2025 guidance to 10.800-10.900 EPS.

Johnson & Johnson Trading Up 6.2%

Shares of NYSE:JNJ opened at $164.78 on Thursday. The stock has a market capitalization of $396.47 billion, a PE ratio of 18.33, a P/E/G ratio of 2.12 and a beta of 0.41. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm has a fifty day moving average price of $153.95 and a 200 day moving average price of $154.71. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.16%. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

Wall Street Analyst Weigh In

JNJ has been the topic of several research reports. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Leerink Partnrs cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Bank of America lifted their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Thursday. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Finally, Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $172.24.

Institutional Investors Weigh In On Johnson & Johnson

An institutional investor recently raised its position in Johnson & Johnson stock. Brighton Jones LLC increased its holdings in Johnson & Johnson (NYSE:JNJ) by 13.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,876 shares of the company’s stock after purchasing an additional 6,332 shares during the period. Brighton Jones LLC’s holdings in Johnson & Johnson were worth $7,502,000 at the end of the most recent reporting period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.